grant
Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate Cancer
Organization UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONLocation HOUSTON, UNITED STATESPosted 15 Apr 2025Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY2026AddressAdverse ExperienceAdverse eventAffinityAntibody-drug conjugatesAntigen TargetingAsialiaAssayBeta ParticleBeta RadiationBeta RaysBindingBioassayBiodistributionBiological AssayBiological MarkersBloodBlood Reticuloendothelial SystemBody TissuesCancer PatientCastrationCell BodyCell LineCellLineCellsCharged Particles-Electrons RadiationChelating AgentsChelatorsCitrullineClinicalClinical DataComplexonsCryptophycinCustomDNA DamageDNA InjuryDataDetectionDevelopmentDiagnosticDiseaseDisease ProgressionDisorderDoseDrug KineticsDrug TargetingDrugsEligibilityEligibility DeterminationEsteroproteasesFDA approvedFOLHFOLH1FOLH1 geneFolate Hydrolase 1FoundationsGCP2Glutamate Carboxypeptidase IIGlutamatesGoalsHistopathologyHyposalivationImageInterruptionInvestigatorsL-GlutamateL-ValineLabelMalignant neoplasm of prostateMalignant prostatic tumorMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMediatingMedicationMiceMice MammalsMicro-tubuleMicrotubulesModelingMolecular InteractionMolecular TargetMouth DrynessMurineMusN-Acetylated Alpha-Linked Acidic Dipeptidase 1NAALAD1NAALADase INormal CellOrganOutcomePDX modelPETPET ScanPET imagingPETSCANPETTPSMPSMAPatient derived xenograftPatientsPeptidasesPeptide HydrolasesPerformancePharmaceutical PreparationsPharmacokineticsPhasePositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPropertyProstate CAProstate CancerProstate malignancyProstate-Specific Membrane AntigenProtease GeneProteasesProteinasesProteolytic EnzymesProtocolProtocol ScreeningProtocols documentationPublic HealthRad.-PETRadioactiveRadioactive IsotopesRadioisotopesRadiolabeledRadionuclidesReactionRecurrent NeoplasmRecurrent tumorRefractoryResearchResearch PersonnelResearchersResistanceRiskSafetySalivary GlandsSalivary hypofunctionStrains Cell LinesSurgical CastrationSurvival RateTestingTherapeuticTherapeutic EffectTissuesValineVisualizationWorkXerostomiaXerostomicadvanced prostate canceranalogandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate canceraptyalismbio-markersbiologic markerbiomarkercastration resistant CaPcastration resistant PCacastration resistant prostate cancercell killingchemotherapyclinical translationclinical validationclinically translatablecultured cell linecustomscytotoxicdevelopmentaldrug developmentdrug/agentdry mouthefficacy testingexperienceglutamatergichormone refractory prostate cancerimagingimprovedimproved outcomein vivoinhibitorirradiationmenmouse modelmulti-modalitymultimodalitymurine modelneoplasm recurrencenew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapynuclear imagingoral drynessoverexpressoverexpressionpatient derived xenograft modelpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographyprecision medicineprecision-based medicineprostate cancer cellprostate cancer resistant to androgenprostate tumor cellprototyperadiolabelradiolabelingradiolabelsradioligand therapeuticradioligand therapyradioligand treatmentradiologically labeledradiotracerresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponsesalivary gland hypofunctionsmall moleculestandard of caretargeted agenttargeted biomarkertargeted drug therapytargeted drug treatmentstargeted imagingtargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttheranosticstherapeutic outcometherapeutic resistancetherapy outcometherapy resistanttooltreatment resistancetumoruptakevirtualβ-Particleβ-Rays
Description preview
PROJECT SUMMARY
The goal of this proposal is to develop a targeted therapy for treatment of metastatic castration-resistant prostate
cancer (mCRPC). There is currently no cure for this disease and available therapies leave significant room for
improvement based on dismal survival rates. Prostate-specific membrane antigen (PSMA) is a clinically…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click